S tarting in 2012, the Centers for Medicare and Medicaid Services (CMS) instituted a value-based purchasing (VBP) program for most U.S. hospitals. Under this program, participating hospitals have their base operating Diagnosis-Related Group (DRG) payments reduced by a small percentage each year (1.5% for fiscal year 2015). The amount that is withheld is then given back, in the form of incentives, to hospitals that exceed the 50th percentile of all hospitals' performance for selected metrics, including risk-adjusted mortality (1, 2) . CMS has instituted a differently structured but similarly themed initiative under the Hospital Readmissions Reduction Program (3) . Fear of financial penalties along with concern about the effect of public reporting on hospital reputation have resulted in hospitals putting great effort into improving performance on these metrics (4) . Pneumonia was a clear choice for inclusion in the VBP and Hospital Readmission Reduction Program (HRRP) programs because it is the most common infectious diagnosis in U.S. hospitals, with aggregate costs of U.S. hospitalizations exceeding $10 billion in 2011 (5, 6) .
In the years since the introduction of quality metrics for pneumonia, however, new evidence has indicated that the choice of codes used to define pneumonia has important implications for monitoring trends in outcomes over time and in evaluating and comparing hospital performance. This is especially relevant for calculating pneumonia mortality and readmission rates. For example, large declines observed in case fatality for patients hospitalized with pneumonia between 2003 and 2009 suggested better outcomes for patients with this condition (7) , but further research revealed that mortality changed very little when patients with a secondary diagnosis of pneumonia and principal diagnosis of sepsis or respiratory failure were included in the cohort (8) . These findings suggested that although improvements in care might have occurred, another explanation for the declining mortality rate among the cohort with a principal diagnosis of pneumonia was that the sickest pneumonia patients had, over time, become more likely to receive a principal diagnosis of sepsis or respiratory failure. In a follow-up study, the same group of investigators found that assignment of a principal diagnosis of sepsis or respiratory failure varied across hospitals, with some hospitals never using these codes in the principal position and others coding up to 75% of pneumonia patients with these principal diagnoses (intraquartile range, 18-34%) (9) . The authors observed that changing pneumonia cohort inclusion criteria to include principal diagnosis sepsis or respiratory failure led to reclassification of "outlier" status for one third of hospitals (9) .
There are a number of possible explanations for the variation in use of codes across hospitals. First, it is almost certain that there are true differences in case mix across hospitals. Some hospitals simply have more cases of respiratory failure and sepsis in pneumonia than others. Nevertheless, the extreme variation observed in the use of these codes is difficult to justify on clinical grounds alone. Second, recent initiatives, including the Surviving Sepsis Campaign (10), have improved recognition of sepsis by clinicians, although the penetrance of this knowledge is likely to vary across hospitals. Third, there are differences in documentation and coding unrelated to gaming. Because patients who meet criteria for sepsis and respiratory failure are far sicker and more expensive than pneumonia patients who do not meet these criteria, hospitals have made attempts to improve coding of sepsis and respiratory failure. Through better documentation and coding, hospitals can recoup these costs because sepsis and respiratory failure fall into a higherpaying DRG. A final explanation for this variation, which is the focus of the article by Sjoding et al (11) in this issue of Critical Care Medicine, is gaming by hospitals to influence performance on hospital quality measures. By gaming, the authors mean that hospitals purposefully code a higher percentage of marginal pneumonia patients with principal diagnoses of sepsis and respiratory failure in order to change their performance ranking for VBP or HRRP purposes.
Sjoding et al (11) used simulation methods to examine the impact of changes in coding on hospital rankings for pneumonia mortality and readmission. They were specifically interested in how gaming might change a hospital's performance ranking. They also used simulation techniques to explore whether increasing prevalence of coding sepsis and respiratory failure might make it more difficult to be a high performer without engaging in the practice. The authors identified Medicare patients with principal diagnosis pneumonia (because CMS uses this definition for calculating riskadjusted mortality and readmission rates) and then, using simulation, excluded a percentage of patients who met diagnostic criteria for sepsis or respiratory failure. They varied both the percentage of admissions that were recoded and the number of hospitals that engaged in the recoding because as more hospitals engaged in the practice, the mean mortality rate changed.
When 100 hospitals with mortality rates above the 50th percentile recoded all eligible patients as principal diagnosis sepsis or respiratory failure, 41 hospitals dropped below the 50th percentile, greatly reducing the likelihood that they would face financial penalties under VBP. Findings were similar but less pronounced for risk-standardized readmission rates. As more hospitals engaged in recoding, overall mortality and readmission rate declined, making the effect of recoding more pronounced. When 50% of hospitals engaged in recoding, hospitals that engaged in the practice improved their ranking by 242 places, on average, and hospitals that did not worsened their rankings by 241 places. The authors concluded that, given variation in coding across hospitals and the increasing need to recode as more hospitals engage in the practice, CMS should consider including principal diagnosis sepsis and respiratory failure (with secondary diagnosis pneumonia) in their pneumonia definition.
This suggested change, although sensible, raises additional questions. One obvious concern is that patients with a principal diagnosis of sepsis and a secondary diagnosis of pneumonia might have been admitted with a nonpulmonary infectious diagnosis and developed pneumonia as a complication. To address this, it has been suggested that only patients with pneumonia marked "present on admission" (POA) should be included in the metric (8, 9) . POA was introduced in 2008, and its use by hospitals has increased rapidly since its introduction (12). However, the use of POA codes still varies across hospitals (13), which could pose challenges in identifying patients with POA pneumonia. Use of the POA code to define pneumonia is likely to improve over time. Still, in the case of the pneumonia mortality and readmission metrics, there might also be some incentive for continuing to use POA codes intermittently. This is because hospitals could remove the sickest patients with pneumonia from both the numerator and denominator by leaving off the pneumonia POA indicator in patients with sepsis and respiratory failure.
Risk adjustment presents an additional dilemma. One interesting finding of the current study is that that the impact of recoding was greater for mortality compared with readmission. This is a function of the larger differential in the mortality rates of patients with principal diagnosis sepsis or respiratory failure compared with patients with pneumonia (9). If sepsis and respiratory failure patients were to be included in the metric, hospitals with more of these cases might, justifiably, express concern that the patient's severity of illness at the time of admission is not fully accounted for in CMS's mortality and readmission models (which include demographics and comorbidities). One possible solution to the problem of risk adjustment would be to include sepsis or respiratory failure as covariates in the CMS outcome models. Yet this adjustment could perpetuate the same problems that changing the cohort definition is intended to solve-as it would "reward" hospitals that had a lower threshold for using the codes (9) . Ideally, future measures would incorporate clinical information from the electronic medical record, such as vital signs and admission laboratory data, to better assess severity on presentation.
Regardless of CMS's final decision on this issue, Sjoding et al (11) have confirmed prior work that suggested that recoding affects hospital risk-adjusted mortality rates and thus performance status. They are the first to suggest that readmission is affected in a similar but attenuated way and are also the first to describe that the coding behavior of other hospitals can be an important modifier in this equation. This work raises important questions about how to best measure hospital performance for pneumonia mortality and readmission. It appears that under the current definition, variation in use of diagnostic codes across hospitals has the potential to greatly impact hospital performance. The approach to measure development and revision must therefore be thoughtful, with efforts directed at constructing measures that are resilient and minimize the impact of attempted gaming. Does Haloperidol Cause Delirium?* D elirium is a common management problem in the ICU with prevalence estimates ranging between 8% and 57% depending on the case mix (1). It is associated with both morbid and mortal outcomes (2) . It is treated with a variety of therapies-both pharmacologic and nonpharmacologic-including haloperidol (3) . Haloperidol is a butyrophenone antipsychotic with activity at central dopamine receptors (3) . Randomized controlled trials (1, (4) (5) (6) (7) and an observational study (8) have examined the utility of haloperidol for the prevention (4) and management of delirium in the ICU (5) (6) (7) (8) (9) . The results have been mixed with some studies showing benefit (4, 5) and others showing no difference from the comparator (7) or a lack of efficacy (6) or inferiority (9) . All suffer from trial design flaws and none have examined mortality as the primary outcome.
Current guidelines for the management of delirium do not recommend haloperidol use for either prevention or management of delirium (2) . The only trial to suggest that haloperidol may actually increase the risk of delirium was performed by Pisani et al (8) . That prospective observational trial observed 173 ICU patients with delirium who survived their ICU stay. Using a logistic regression analysis, the authors determined that haloperidol administration was associated with an odds ratio of 2.85 for persistent delirium. The varying time points for haloperidol administration (including first-dose administration on the day of ICU discharge) and confounders such as duration of therapy make interpretation of the data difficult to generalize. It is this background that makes the follow-up study by Pisani et al (10) novel both in its design and observations.
In this issue of Critical Care Medicine, the study by Pisani et al (10) was a prospective cohort study in a single-center medical ICU. Using a statistical technique known as marginal structural monitoring (MSM) (11), the authors determined that haloperidol may have a 5% risk (confidence interval, 2-9%) of increasing delirium. MSM is typically employed to reduce bias in the interpretation of observational studies with time-dependent confounders-in this case, multiple drugs (including haloperidol) and interventions such as mechanical ventilation were employed at different times within a patient's ICU course. The technique theoretically allows for a causal inference to be made, even in observational studies, if all confounders have been identified.
As the authors acknowledge, the determination of a causal inference is often difficult to conclude in an observational study, as all confounders may not be known and/or their effect difficult to quantify. The biggest confounder limiting our ability to interpret the results of the study by Pisani et al (10) was their inability to adjust for the use of lorazepam due to the risk of collinearity with fentanyl.
Lorazepam is experimentally more clearly associated with delirium than haloperidol (2) . Intrinsic to the MSM analysis is weighting by the inverse probability of treatment. Although the investigators made an attempt to address this issue, the inverse weighting can amplify errors in the estimate (12) and, therefore, the association between haloperidol and any increased risk of delirium may not be a robust estimate and should be interpreted with caution. It is also important to note that the effect of haloperidol on delirium was dwarfed by other factors such as mechanical ventilation (> 500% risk of next-day delirium).
Notwithstanding these criticisms, the use of this alternative statistical technique has allowed for novel information. The authors provide a snapshot of sedation practices in their unit, and while typical of many practices in the overall application of sedation, the specifics may be difficult to replicate and therefore the results difficult to generalize.
The study by Pisani et al (10) is provocative and suggests a need to reevaluate the use of haloperidol for the management
